Browsing Tag
Vizz
2 posts
LENZ Therapeutics (NASDAQ: LENZ) cuts 75% of jobs after VIZZ Q3 sales reach $2.6m
LENZ Therapeutics is cutting three-quarters of its workforce and changing CEOs despite accelerating VIZZ prescriptions, betting that a much smaller organisation can market its new presbyopia drug more efficiently.
Viatris and the presbyopia drug race: What ASCRS 2026 data means for the MR-141 FDA decision in October
Viatris presents full VEGA-3 Phase 3 data for MR-141 presbyopia drop at ASCRS 2026. FDA PDUFA date is October 17, 2026. Market context, competitive landscape, and investor outlook.